The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Oncology & Cancer

Breathing Engineered Bacteria: A New Approach to Treating Lung Disease
Genetically Modified Organisms & Synthetic Biology

Breathing Engineered Bacteria: A New Approach to Treating Lung Disease

AUG 10, 2026
Kanvas Biosciences Secures $48M Series A to advance lead immuno-oncology drug
Finance

Kanvas Biosciences Secures $48M Series A to advance lead immuno-oncology drug

MAY 8, 2026
Traces of bacteria inside brain tumors may affect tumor behavior
Basic & Discovery Research

Traces of bacteria inside brain tumors may affect tumor behavior

NOV 24, 2025
MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
Editor's Choice

MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline

SEP 4, 2025
Towards a diagnostic test: the gut microbiome as a clinical target for screening for colorectal cancer
Basic & Discovery Research

Towards a diagnostic test: the gut microbiome as a clinical target for screening for colorectal cancer

JUL 2, 2025
MaaT Pharma Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg®
Finance

MaaT Pharma Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg®

JUN 3, 2025
Changes in microbiome predict risk for sexually transmitted disease
Basic & Discovery Research

Changes in microbiome predict risk for sexually transmitted disease

JAN 22, 2025
MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study
Clinical & Manufacturing

MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study

JAN 8, 2025
Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer
Clinical & Manufacturing

Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer

DEC 17, 2024
Possible colon cancer vaccine target uncovered in bacteria
Oncology & Cancer

Possible colon cancer vaccine target uncovered in bacteria

DEC 12, 2024
Updates from MaaT Pharma’s Early Access Program Demonstrate Prolonged Long-Term Survival in Patients Receiving MaaT013
Oncology & Cancer

Updates from MaaT Pharma’s Early Access Program Demonstrate Prolonged Long-Term Survival in Patients Receiving MaaT013

NOV 8, 2024